| Autor: |
Bijaya Mohanty, Ashok Sunder, Bhagyalakshmi Satyanarayan, Manish Kumar, Rajiv Shukla, Asif Ahmed |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
Journal of Family Medicine and Primary Care, Vol 10, Iss 11, Pp 4236-4241 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2249-4863 |
| DOI: |
10.4103/jfmpc.jfmpc_578_21 |
| Popis: |
Introduction: After the first case of Covid-19 was identified in Wuhan City, China, the numbers increased rapidly all over the world putting a huge burden on the entire healthcare system. Managing these cases posed a great challenge to the treating clinicians in the absence of targeted therapy. At this juncture, few modalities got approved as EUA (Emergency use under authorization) drugs namely Remdesivir, Convalescent Plasma (CP), and Tocilizumab (TCZ) to treat this deadly disease. Aim: To analyze the success rates of EUA therapies for Covid-19 pneumonia in our hospital. Materials and Methods: This was a prospective observational study conducted from April 2020 to October 2020 in the department of Medicine at Tata Main Hospital, Jamshedpur, Jharkhand. All adults with moderate to severe Covid-19 as per the WHO criteria were enrolled in the study with their informed consent. Patients with estimated glomerular filtration rate |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
